Geode Capital Management
SABS icon

Geode Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Geode Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.36M Buy
1,376,387
+99,202
+8% +$361K ﹤0.01% 2923
2026
Q2 		$4.98M Buy
1,277,185
+975,149
+323% +$3.63M ﹤0.01% 2921
2026
Q1 		$1.16M Buy
302,036
+182,519
+153% +$728K ﹤0.01% 3315
2025
Q4 		$447K Buy
119,517
+33,799
+39% +$111K ﹤0.01% 3623
2025
Q3 		$172K Buy
85,718
+946
+1% +$2.14K ﹤0.01% 3971
2025
Q2 		$148K Buy
84,772
+87
+0.1% +$144 ﹤0.01% 3963
2025
Q1 		$114K Buy
84,685
+4,451
+6% +$10.2K ﹤0.01% 3999
2024
Q4 		$307K Buy
80,234
+12,692
+19% +$41.7K ﹤0.01% 3752
2024
Q3 		$182K Buy
67,542
+8,127
+14% +$22.5K ﹤0.01% 3930
2024
Q2 		$184K Sell
59,415
-4,051
-6% -$14.9K ﹤0.01% 3945
2024
Q1 		$288K Buy
63,466
+27,830
+78% +$153K ﹤0.01% 3811
2023
Q4 		$245K Hold
35,636
– – ﹤0.01% 3865
2023
Q3 		$225K Buy
35,636
+5,583
+19% +$41K ﹤0.01% 3935
2023
Q2 		$249K Hold
30,053
– – ﹤0.01% 3944
2023
Q1 		$132K Hold
30,053
– – ﹤0.01% 4236
2022
Q4 		$177K Sell
30,053
-1,613
-5% -$14.7K ﹤0.01% 4162
2022
Q3 		$221K Hold
31,666
– – ﹤0.01% 4153
2022
Q2 		$459K Buy
31,666
+1,555
+5% +$32.6K ﹤0.01% 3821
2022
Q1 		$1.13M Buy
30,111
+770
+3% +$35.5K ﹤0.01% 3558
2021
Q4 		$2.29M Buy
+29,341
New +$2.75M ﹤0.01% 3300

Other funds holding SABS

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Propel Bio Management
Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management's SABS Position: Q3 2026 in Review

Geode Capital Management increased its SAB Biotherapeutics (SABS) stake by 7.8% in Q3 2026, buying an estimated $361K and bringing the position to 1,376,387 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

Geode Capital Management first reported a position in SABS in Q4 2021 and has held it in 20 quarters since. The position peaked at $4.98M in Q2 2026. 61 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Geode Capital Management held 1,376,387 shares of SAB Biotherapeutics worth $4.36M as of Q3 2026.
  • Geode Capital Management bought 99,202 SAB Biotherapeutics shares in Q3 2026, an estimated $361K.
  • SAB Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2923 holding.
  • Geode Capital Management first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 20 quarters since.
  • Geode Capital Management's SAB Biotherapeutics position peaked at $4.98M in Q2 2026.
  • 61 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.